EU Panel Recommends 4-Week Nivolumab Dosing Schedule in Adjuvant Melanoma

Sep 24, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of nivolumab at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection. “This positive CHMP opinion for … (leggi tutto)